15,16-Dihydrotanshindiol BCAS# 891854-86-7 |
- 15,16-Dihydrotanshindiol C
Catalog No.:BCN3214
CAS No.:891854-96-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 891854-86-7 | SDF | Download SDF |
| PubChem ID | 102004773 | Appearance | Red powder |
| Formula | C18H18O5 | M.Wt | 314.3 |
| Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (6R,7S)-6,7-dihydroxy-1,6-dimethyl-2,7,8,9-tetrahydro-1H-naphtho[1,2-g][1]benzofuran-10,11-dione | ||
| SMILES | CC1COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCC(C4(C)O)O | ||
| Standard InChIKey | HSWJBFKCVPRBJO-AJJMNOOBSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
15,16-Dihydrotanshindiol B Dilution Calculator
15,16-Dihydrotanshindiol B Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.1817 mL | 15.9084 mL | 31.8167 mL | 63.6335 mL | 79.5418 mL |
| 5 mM | 0.6363 mL | 3.1817 mL | 6.3633 mL | 12.7267 mL | 15.9084 mL |
| 10 mM | 0.3182 mL | 1.5908 mL | 3.1817 mL | 6.3633 mL | 7.9542 mL |
| 50 mM | 0.0636 mL | 0.3182 mL | 0.6363 mL | 1.2727 mL | 1.5908 mL |
| 100 mM | 0.0318 mL | 0.1591 mL | 0.3182 mL | 0.6363 mL | 0.7954 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- SCH900776 S-isomer
Catalog No.:BCC1936
CAS No.:891494-64-7
- MK-8776 (SCH-900776)
Catalog No.:BCC3817
CAS No.:891494-63-6
- Betulin caffeate
Catalog No.:BCN4438
CAS No.:89130-86-9
- Odoratisol A
Catalog No.:BCN7813
CAS No.:891182-93-7
- 4-O-Demethylisokadsurenin D
Catalog No.:BCN6650
CAS No.:89104-59-6
- BAMB-4
Catalog No.:BCC5428
CAS No.:891025-25-5
- 24,25-Epoxytirucall-7-en-3,23-dione
Catalog No.:BCN4437
CAS No.:890928-81-1
- GSK 650394
Catalog No.:BCC4070
CAS No.:890842-28-1
- ML 349
Catalog No.:BCC5612
CAS No.:890819-86-0
- VU 1545
Catalog No.:BCC7649
CAS No.:890764-63-3
- VU 29
Catalog No.:BCC7936
CAS No.:890764-36-0
- erythro-Guaiacylglycerol beta-coniferyl ether
Catalog No.:BCN1315
CAS No.:890317-92-7
- 1,2-Didehydrocryptotanshinone
Catalog No.:BCN3122
CAS No.:891854-92-5
- 15,16-Dihydrotanshindiol C
Catalog No.:BCN3214
CAS No.:891854-96-9
- Efaroxan hydrochloride
Catalog No.:BCC6797
CAS No.:89197-00-2
- Fraxiresinol 1-O-glucoside
Catalog No.:BCN4439
CAS No.:89199-94-0
- Mulberrofuran H
Catalog No.:BCN3371
CAS No.:89199-99-5
- LY2334737
Catalog No.:BCC4060
CAS No.:892128-60-8
- Manidipine
Catalog No.:BCC4404
CAS No.:89226-50-6
- Manidipine 2HCl
Catalog No.:BCC4405
CAS No.:89226-75-5
- AZD 3988
Catalog No.:BCC5621
CAS No.:892489-52-0
- 2-(Chloromethyl)-4-(4-nitrophenyl)-1,3-thiazole
Catalog No.:BCC8372
CAS No.:89250-26-0
- MF63
Catalog No.:BCC1744
CAS No.:892549-43-8
- 2,4-Dihydroxy-3-nitropyridine
Catalog No.:BCC8499
CAS No.:89282-12-2
A novel multiplex polymerase chain reaction assay for detection of both HLA-A*31:01/HLA-B*15:02 alleles, which confer susceptibility to carbamazepine-induced severe cutaneous adverse reactions.[Pubmed:28884973]
HLA. 2017 Dec;90(6):335-342.
HLA-A*31:01 and HLA-B*15:02 have been widely reported to confer genetic susceptibility to carbamazepine (CBZ)-induced severe cutaneous adverse reactions (SCARs). Accordingly, the screening for these alleles has been highly recommended to prevent SCAR prior to introducing CBZ therapy. Although a number of methods are available for screening of HLA-A*31:01 or HLA-B*15:02 alleles separately, developing an assay that can detect both these alleles would be more clinically practical, cost-effective and less time-consuming. Therefore, in this study, a multiplex polymerase chain reaction (PCR) using TaqMan Probe was designed and validated to be able to detect HLA-A*31:01 and HLA-B*15:02. In comparison with Luminex-SSO/SBT/SSB, the multiplex PCR assay for detection of HLA-A*31:01 and HLA-B*15:02 had a perfect agreement in the validation group of 125 samples. The method was able to detect the target genes at the DNA concentration of 0.037 ng/muL. The unit cost of this assay is less than $5 USD with total time of 110 minutes.
Identification of the novel allele, HLA-B*15:388, in a Chinese bone marrow donor.[Pubmed:28963780]
HLA. 2018 Feb;91(2):135-136.
The novel allele, HLA-B*15:388, was identified in a Chinese bone marrow donor by sequence-based typing.
Knowledge and practices of chronic hepatitis B virus testing by general practitioners in Victoria, Australia, 2014-15.[Pubmed:28892601]
Aust Fam Physician. 2017 Sep;46(9):683-689.
BACKGROUND: More than one-third of people living with chronic hepatitis B virus (HBV) in Australia have not been diagnosed. The aim of this study was to assess general practitioners' (GPs') knowledge and practices regarding chronic HBV diagnosis, and identify opportunities to improve testing rates. METHODS: A cross-sectional survey was conducted with GPs working in Victoria, Australia. Statistically significant adjusted odds ratios for high knowledge, and ordering two or more HBV tests per week were calculated. RESULTS: Of 1000 GPs who were invited to participate, 232 completed the survey. Chronic HBV knowledge, use of interpreters, and awareness of HBV testing guidelines were low. Chronic HBV knowledge and testing were associated with age and graduation from a medical school outside Australia. Testing was also associated with gender. DISCUSSION: This study identified gaps in GPs' knowledge about chronic hepatitis. Several barriers to improving testing rates among at-risk populations were identified. We recommend revision of the guidelines for prevention in general practice, and educational activities to improve knowledge of at-risk populations for chronic HBV in Australia.
[Molecular characterization of non-vaccine Streptococcus pneumoniae serotypes 11A, 15 B/C and 23A recovered from invasive isolates in Colombia].[Pubmed:28968016]
Biomedica. 2017 Sep 1;37(3):390-396.
INTRODUCTION: A total of 192 invasive Streptococcus pneumoniae isolates, from serotypes 11A, 15B/C and 23A (not included in the conjugated vaccines), were collected in Colombia between 1994 and 2014 as part of the activities of the Network surveillance system for the causative agents of pneumonia and meningitis (SIREVA II). OBJECTIVE: To determine the molecular characteristics of invasive S. pneumoniae isolates from serotypes 11A, 15B/C and 23A in Colombia from 1994 to 2014. MATERIALS AND METHODS: The molecular characterization of the isolates was carried out through Pulse-Field Gel Electrophoresis (PFGE) and Multilocus Sequence Typing (MLST). RESULTS: Serotype 11A showed one clonal group represented by ST62. Serotype 15B/C was composed of three groups associated with Netherlands15B-37 ST199 (28.75%), ST8495 (18.75%), and SLV (Single-Locus Variant) of ST193 (21.25%). Isolates from serotype 23A were gathered in three clonal groups, with 70.21% closely related to ST42, 17.02% to Colombia23F-ST338, and 6.38% to Netherlands15B-37 ST199. CONCLUSION: Clones Colombia23F-ST338 and Netherlands15B-ST199 covered more serotypes than those previously found by other authors, including serotype 23A. These analyses reveal the importance of capsular switching in the spreading of successful clones among non-vaccine serotypes causing invasive pneumococcal disease.
